FDA red and green lights: October 2025
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
GSK’s trio of cancer discontinuations
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
Blenrep against the odds
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
ESMO 2025 movers – FDA volte-face to the rescue
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
